Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Cellular senescence
Research brief

Shorter leukocyte telomeres in young relapsing-remitting MS patients than in matched controls

In a cross-sectional abstract, young adults with relapsing-remitting MS had shorter leukocyte telomeres than age- and sex-matched healthy controls; shelterin gene variants showed no association with telomere length. [1]

Automatic summary · not editorially reviewed

The key findings

  1. In this cross-sectional study, relative leukocyte telomere length was measured in 40 patients with relapsing-remitting MS aged 40 or younger and 39 age- and sex-matched healthy controls. [1]

  2. Leukocyte telomere length was significantly shorter in the RRMS group than in controls (p = 0.005), with modest group discrimination (area under the curve 0.698). [1]

  3. Across all inheritance models, the TERF1 and TERF2 variants showed no significant association with telomere length. [1]

The source at a glance

Study type / format
Cross-sectional study (abstract)
Population / context
Adults aged 40 or younger with relapsing-remitting MS (n = 40) and age- and sex-matched healthy controls (n = 39).
Summary based on
Study abstract
Original publication
October 6, 2026

Young RRMS cohort compared with matched healthy controls

The abstract describes a cross-sectional study. Relative leukocyte telomere length was measured by quantitative polymerase chain reaction in 40 patients with relapsing-remitting MS aged 40 or younger and in 39 healthy controls matched for age and sex. Key shelterin complex variants were also genotyped: TERF1 (rs10107605, rs1545827) and TERF2 (rs251796). Genetic association testing covered several inheritance models and was combined with correlations to clinical and imaging features.

Supporting source [1]

Shorter telomeres in RRMS; no link to shelterin variants

Telomere length was significantly shorter in the RRMS group than in controls (p = 0.005), which the authors describe as evidence of accelerated biological aging even in this relatively young cohort. Discrimination between groups was modest: area under the curve 0.698 (95% confidence interval 0.60–0.79). Across all inheritance models, the TERF1 and TERF2 variants showed no significant association with telomere length. Subgroup analyses reported that telomere shortening was independent of chronological age, sex, smoking status and disease duration.

Supporting source [1]

Abstract-only scope of a cross-sectional telomere study

These findings come from the abstract; the full text was not reviewed. The design is cross-sectional, so it shows an association at one time point, not that MS causes telomere shortening. The authors interpret the pattern as consistent with disease-driven immunosenescence and call telomere length a promising biomarker, but the abstract reports no longitudinal or outcome data. The proposed future longitudinal multi-omics work is a suggestion, not a completed result.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. The cross-sectional design cannot establish causation or temporal order, and the abstract reports no longitudinal or clinical outcome data.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Shorter Leukocyte telomere length as a marker of biological aging in relapsing-remitting multiple sclerosis.

Karacan I, Susgun S, Savasci D, Yigit B, Yozlu D, Korkmaz ND, Duzenli OF, Yabaci A, Yucesan E, Gursoy AEB. · europepmc.org · October 6, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    age- and sex-matched healthy controls (n =
  2. Finding 2 ↑

    LTL was significantly shorter in RRMS patients
  3. Finding 3 ↑

    exhibited no significant association with LTL

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…